Chiron Real Estate Inc. (XRN) Stock
XRN has an Alpha Score of 50 out of 100 (weak), computed on Nov 10, 2026 from 3 of 4 sub-scores. 4 of the hedge funds AlphaScala tracks reported XRN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Citadel's at $1.81M. Company insiders reported 3 open-market buys and 0 sales on SEC Form 4 in the 90 days to Nov 9, 2026. Its trailing P/E ratio is 6.6 and its net margin 37.8% (key statistics as of Nov 10, 2026).
What is XRN's Alpha Score?
How it works →Alpha Score of 50 reflects moderate overall profile with poor momentum, strong value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 10, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own XRN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Citadel Ken Griffin | 48K | $1.81M | +111% |
| Marshall Wace | 18K | $688.3K | NEW |
| D.E. Shaw David Shaw | 16K | $611.4K | NEW |
| Renaissance Technologies Jim Simons (founder) | 14K | $536.4K | -23% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Chiron Real Estate Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Aug 17, 26 | Whitlock Matthew Fitzsimmons | Chief Investment Officer | BUY | 500 | $18K |
| Aug 14, 26 | Whitlock Matthew Fitzsimmons | Chief Investment Officer | BUY | 500 | $19K |
| Aug 12, 26 | Roseth Aaron Robert | COO | BUY | 13.5K | $496K |
| Aug 11, 26 | Fitzgerald Charles | Director | BUY | 14.0K | $501K |
| Aug 11, 26 | Decker Mark Okey Jr | CEO and President | BUY | 550 | $20K |
| Aug 11, 26 | Decker Mark Okey Jr | CEO and President | BUY | 6.9K | $247K |
| Aug 10, 26 | Fitzgerald Charles | Director | BUY | 27.6K | $992K |
| Aug 10, 26 | Decker Mark Okey Jr | CEO and President | BUY | 8.0K | $287K |
SEC Form 4 filings as of Nov 9, 2026
See cluster-buy signals across all tickers →What are XRN's key statistics?
Key statistics as of Nov 10, 2026
How does XRN's valuation compare with the Real Estate sector?
| Metric | XRN | Real Estate median | Companies in median |
|---|---|---|---|
| P/E ratio | 6.6 | 27.4 | 66 |
| Net margin | 37.77% | 16.49% | 72 |
| Return on equity | 10.77% | 7.17% | 74 |
| Dividend yield (payers) | 8.98% | 4.71% | 61 |
Medians over the Real Estate stocks whose key statistics were refreshed in the last 35 days (newest Nov 10, 2026). P/E excludes loss-making companies.
XRN price chart
Powered by TradingViewWhat does Chiron Real Estate Inc. do?
Global Medical REIT Inc. is a net-lease real estate investment trust specializing in healthcare facilities. Founded in 2011 and headquartered in Maryland, the company acquires state-of-the-art, purpose-built medical office buildings and leases them primarily to physician groups and regional or national healthcare systems. With a portfolio comprising over 190 buildings and more than 5 million leasable square feet, Global Medical REIT supports a diverse tenant base delivering critical healthcare services across various U.S. regions. Its business model focuses on generating stable, risk-adjusted returns through long-term leases with established healthcare operators. The company emphasizes sustainable and responsible investment practices through environmental, social, and governance initiatives. Global Medical REIT plays a strategic role in the healthcare real estate sector by providing essential infrastructure that enables modern, localized medical care delivery, thereby facilitating healthcare providers in expanding services and improving patient access.